FindTrial
Sign In

GTAEXS617

DRUG2 trials

Sponsors

Exscientia AI Limited, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Conditions

Advanced solid tumorsHead and Neck Squamous Cell Carcinoma (HNSCC)Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast CarcinomaNon-small Cell Lung Cancer (NSCLC)Pancreatic AdenocarcinomaPlatinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)Triple Negative Breast Cancer (TNBC)

Phase 1

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RecruitingNCT05985655
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Head and Neck Squamous Cell Carcinoma (HNSCC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Non-small Cell Lung Cancer (NSCLC) +3
Start: 2023-07-06End: 2028-05-01Target: 230Updated: 2026-02-12
A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors
RecruitingCTIS2023-508227-13-00
Exscientia AI LimitedAdvanced solid tumors
Start: 2023-06-19Target: 112Updated: 2026-01-14